Vycor Medical, Inc. reported substantial improvement in key financial metrics for the year ended December 31, 2025, with total revenue reaching $1,863,400, representing a 17% increase over 2024. The company's Vycor Medical division, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, saw revenues increase by 18% over the previous year, with most growth coming from international markets as part of a key company strategy. This international expansion represents a significant development for the company, though sales growth continued in the United States as well.
The VBAS division generated $1,796,070 of the company's total revenue, while the NovaVision division, which remains in development and offers therapy programs for visual disorders after stroke or brain injury, contributed $67,330. Clinical validation played a significant role in the company's progress during 2025, with seven new peer-reviewed studies published on the ViewSite Brain Access System, bringing the total published peer-reviewed clinical papers to 50, with an additional 14 other clinical papers. These studies reflected increasing international spread of VBAS clinical data, with papers published in the United States, United Kingdom, Japan, and Mexico, all highlighting clinical advantages including reduced brain tissue damage, improved patient outcomes, and reduced hospital stay. For an overview of Vycor Medical's VBAS see https://www.vycormedical.com.
A new clinical study on NovaVision's NeuroEyeCoach was also published during 2025, comparing results from using the program at home versus in a clinic. The study concluded that both home-based and clinic-based patients showed meaningful improvements with no significant differences between the two settings in activities of daily living improvements, validating NeuroEyeCoach as an effective tool whether used clinically or accessed remotely. This finding is particularly important given the significant drive in healthcare systems worldwide to access digital technologies in home settings.
The company reported operating profit of $33,900 compared to an operating loss of $(9,145) in 2024, while non-GAAP operating profit reached $145,881 compared to $81,245 in the previous year. Gross profit for 2025 was $1,498,295, an 11% increase over 2024, generating a margin of 83% versus 89% in the previous year. The company attributed the margin change to validation, shipping and higher manufacturing costs of new production as well as a higher international sales mix.
On a GAAP basis, the company reported operating expenses of $1,527,207, a net loss of $396,796, and a loss of $0.01 per share for the year ended December 31, 2025. The company's non-GAAP financial measures, which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation, showed operating expenses of $1,415,226, non-GAAP operating profit of $145,881, and non-GAAP net loss of $284,815 or $0.01 per share. Management uses these non-GAAP measures to analyze the period-to-period financial performance of its core business operations, though investors are cautioned to consider them only in conjunction with GAAP financial statements. For the latest information on the company, including media and other coverage, please go online at https://www.vycormedical.com.
